Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALAPRO-3 in DDR-mutated metastatic castration-sensitive prostate cancer
CTR20212191Phase 3Active
- Sponsor
- Pfizer
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of talazoparib, enzalutamide in prostate cancer (PCa), sponsored by Pfizer. Started Jan 2022; status: active.
02
Drugs
talazoparibenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20212191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212191.